FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1) By Ogkologos - April 11, 2025 1327 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-811 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Neoadjuvant Docetaxel, Oxaliplatin, and S-1, as Part of Perioperative Chemotherapy, Prolongs... August 19, 2024 Opinion: ‘We’re making headway, but we can’t be complacent’ February 11, 2021 Are differences in treatment driving variation in ovarian cancer survival internationally? August 11, 2020 Utility of Genomic Profiling Use for Targeted Therapy in a Phase... May 6, 2025 Load more HOT NEWS Assessment of Patients’ Perspective on the Consequences of the COVID-19 Pandemic... Patients Diagnosed with Cancer During Pregnancy May Have Increased Risk of... 2020 round-up: Our biggest cancer stories of the year Talquetamab Continues To Demonstrate High Overall Response Rates in Heavily Pretreated...
